Two novel approaches provide new insights into prognostic markers for rare adrenal cancers
Detecting ctDNA and a simple four-component scoring system showed some predictive value, but require prospective validation
Telemedicine reduces delays in bone sarcoma management in rural India
A model implemented by a non-profit organisation exemplifies how virtual consultation and follow-up of patients with rare cancer can facilitate continuity of care
Long-term nirogacestat shows sustained benefits in desmoid tumours
Newly presented phase III trial and real-world findings reassure on the use of the gamma secretase inhibitor
Real-world data has become integral to sarcoma research
Researchers’ confidence is growing, but the quality of the data generated may still represent a challenge
Rare cancers: research progresses at a slower pace than in other areas of oncology
With its new peer-reviewed journal dedicated to rare tumours, ESMO supports knowledge and data sharing among the stakeholders in the field
Some clinical activity was reported for novel tyrosine kinase inhibitors in previously treated patients with GIST
However, the future of TKI combinations for these rare tumours is uncertain
Prolonged use of adjuvant imatinib shows promise in localised GIST
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care
A new combination treatment shows early promise in GEP-NECs
Lurbinectedin and irinotecan demonstrate a synergic clinical effect in patients with neuroendocrine carcinomas of gastroenteropatic primary site after chemotherapy failure
Can sarcomas benefit from targeted treatments active in other tumour types?
Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours.
New hope for MDM2 inhibition in liposarcomas?
An early-phase trial shows the efficacy of brigimadlin in dedifferentiated and well-differentiated liposarcomas, but confirmation from phase III results is still awaited